In patients with previously treated HER2+ metastatic CRC, T-DXd associated with a response rate of 45% and durable responses.
Neoadjuvant mFOLFIRINOX prior to chemoradiotherapy and total mesorectal excision significantly improved several efficacy outcomes vs preoperative chemoradiotherapy and total mesorectal excision.
The addition of neoadjuvant/adjuvant trastuzumab to neoadjuvant chemoradiotherapy and surgery did not improve DFS, OS, or pCR vs trimodality therapy alone in patients with HER2-positive esophageal adenocarcinoma.
The S1505 trial failed to meet primary endpoint of 2-year OS rate ≥ 58% with perioperative mFOLFIRINOX or gemcitabine/nab-paclitaxel.
In patients with advanced HER2+ gastric/GEJ cancer previously treated with trastuzumab, trastuzumab deruxtecan significantly improved response and OS vs standard chemotherapy.
Improvements in both efficacy (PFS, ORR) and safety with single-agent pembrolizumab vs standard therapy.